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Summary 10 
Objective: The purpose of this review is to describe highlights from original research 11 
publications related to osteoarthritis (OA), epigenetics and genomics with the intention of 12 
recognising significant advances. 13 
Design: To identify relevant papers a Pubmed literature search was conducted for articles 14 
published between April 2016 and April 2017 using the search terms ‘osteoarthritis’ together 15 
with ‘genetics’, ‘genomics’, ‘epigenetics’, ‘microrna’, ‘lncRNA’, ‘DNA methylation’ and 16 
‘histone modification’. 17 
Results: The search term OA generated almost 4000 references. Publications using the 18 
combination of descriptors osteoarthritis and genetics provided the most references (82 19 
references). However this was reduced compared to the same period in the previous year; 20 
8.1% to 2.1% (expressed as a percentage of the total publications combining the terms 21 
osteoarthritis and genetics).  Publications combining the terms osteoarthritis with genomics 22 
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(29 references), epigenetics (16 references), lncRNA (11 references; including the 23 
identification of novel lncRNAs in OA), DNA methylation (21 references), histone 24 
modification (3 references) and microrna (79 references) were reviewed.  Potential OA 25 
therapeutics such as histone deacetylase inhibitors have been identified. A number of non-26 
coding RNAs may also provide targets for future treatments. 27 
Conclusion: There continues to be a year on year increase in publications researching 28 
microRNAs in OA (expressed as a percentage of the total publications), with a doubling over 29 
the last 4 years. An overview on the last year’s progress within the fields of epigenetics and 30 
genomics with respect to OA will be given.  31 
Keywords 32 
Osteoarthritis, genetics, epigenetics, non-coding RNA 33 
Introduction 34 
Epigenetics are a group of genome function mechanisms that do not solely result from the 35 
DNA sequence. The term epigenetics encompasses DNA and chromatin  modifications and 36 
their associated functions as well as non-coding RNAs (ncRNAs).  Epigenetic control of gene 37 
expression is essential for normal organismal development and cellular function. Abrogation 38 
of epigenetic regulation is evident in osteoarthritis (OA). In addition to understanding the 39 
pathogenesis of OA through epigenetic research, abnormal epigenetic profiles may act as 40 
biomarkers for disease stratification or predictors of disease outcome. Thus epigenetics is a 41 
crucial area in the diagnosis, prognosis, and treatment of this disease.  42 
Interestingly not all OA tissues or joints are studied to the same extent, and thus it is difficult 43 
to gain a complete, integrated understanding of the epigenetics systems which contribute to 44 
OA. Whilst this review summarises the main levels of epigenetic control studied over the last 45 
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12 months (between May 2016- May 2017), we also highlight potential additional directions 46 
required by the field.  47 
GENETICS  48 
Genetics of Osteoarthritis 49 
OA is known as a complex heterogeneous disease, in which one of the contributing factors to 50 
disease progression is a genetic component [1, 2]. Genome-wide association studies (GWAS) 51 
has enabled the discovery of novel genetic variants that could be used as prognostic 52 
biomarkers for early diagnosis, or establish risk groups prone to the disease development. 53 
There have been five articles published employing GWAS for discovery of genetic variants 54 
associated with OA this year [3-7] . Most of the variants were found in the non-translated 55 
regions within the genes or on the areas remote from the gene, suggesting the regulatory 56 
changes in genes involved in OA. Whereas changes within the gene itself point to structural 57 
changes of the synthesized proteins related to early OA onset. Styrkarsdottir et al. (2017) [5] 58 
demonstrated a missense variant of the COMP gene (p.Asp369His) and a frameshift mutation 59 
in the CHADL gene (p.Val330Glyfs*106), corresponding to hip replacement surgery on 60 
average 13.5 years and 4.9 years earlier in these patients, respectively. Results from these 61 
studies have discovered novel gene variants, suggesting additional genes involved in OA 62 
progression. Although each has a small effect size, combined with other factors these may 63 
contribute to OA.  64 
Endophenotype studies 65 
Sample size is an important factor in GWAS studies, increasing the power and 66 
consequentially, the number of single nucleotide polymorphisms (SNPs) tested in the 67 
experiment [8]. However, it is not the only feature that can be used in order to find more 68 
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statistically significant genetic variants in heterogeneous diseases such as OA. Stratification 69 
of endophenotypes, in OA particularly can lead to the discovery of novel variants. Recently 70 
published articles (Table 1) clearly demonstrate that using intermediate endophenotypes such 71 
as site of maximal joint space narrowing (maxJSN), bone remodeling, cartilage thickness and 72 
radiographic progression can help to yield more loci than previously reported. 73 
Panoutsopoulou et al. (2016) [3] compared variants in hypertrophic with non-hypertrophic 74 
OA. The most significant variant was located between STT3B and GADL1 genes 75 
(rs6766414), and this association was fully attenuated in non-stratified analyses of all hip OA 76 
cases versus population controls.   77 
Table 1. The use of endophenotypes in OA-related GWAS studies  78 
Joint Endophenotype Sample size  Population; 
study 
Variants Reference 
Hip Radiographic; 
max JSN, bone 
remodelling 
OA;2118, 
Cx;6500 
European; 
arcOGEN 
LRCH1, 
STT3B, 
GADL1, 
STT3B 
Panoutsopoulou 
et al , 2016 [3] 
 
Hip Radiographic; 
min JSN, 
cartilage 
thickness 
OA;13,013, 
Cx;8227 
European, 
US, Asian; 
Rotterdam 
Study I 
Rotterdam 
Study II 
TwinsUK, 
SOF 
MrOS 
TGFA 
PIK3R1 
FGFR3 
TREH 
Castaño-
Betancourt et 
al., 2016 [4] 
Hip No OA;5657, 
Cx;207,514 
Icelandic; 
novel 
COMP 
CHADL 
Styrkarsdottir 
et al., 2017 [5] 
Knee Radiographic 
progression; 
KL 
CHECK;431, 
meta:1603 
European; 
CHECK, 
OAI, Spain 
mtDNA 
variants; 
superhaplogroup 
JT 
Fernandez-
Moreno et al., 
2016 [6] 
Knee 
 
Radiographic; 
definite 
osteophytes, 
min JSN, 
TJR 
OA;3,898, 
Cx;3,168 
North 
American; 
Osteoarthritis 
Initiative, 
Johnston 
County 
Osteoarthritis 
LSP1P3 Yau et al., 2017 
[7] 
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Project, 
Multicenter 
Osteoarthritis 
Study, 
Genetics of 
Osteoarthritis 
study 
OA; osteoarthritis, TJR; total joint replacement, JSN; joint space narrowing, Cx; control, 79 
mtDNA; mitochondrial DNA; CHECK; cohort hip and cohort knee,  meta; meta-analysis. 80 
 81 
EPIGENETICS 82 
Epigenetics play a key role in the development of OA and explains the relationship between 83 
heritable traits, the environment, other factors (particularly ageing in relation to OA, as it is 84 
an age-related disease) and OA itself. DNA plasticity is mediated in part by epigenetic 85 
changes, and it is proposed that it can be passed to subsequent generations. This was studied 86 
in the epidemiological study of the consequences of the Dutch famine which concluded that 87 
early-life environmental conditions can cause epigenetic changes in humans that persist throughout 88 
life [9]. Thus epigenetics establishes that joint health can be affected by the interplay of our 89 
genes and environment in addition to the proposed inherited effects of our ancestors' genes 90 
and environment. Epigenetic traits are both highly dynamic, and tissue specific (indeed even 91 
down to the level of different areas of the same tissue). Epigenetics enables tight control at 92 
the transcriptional level via gene expression (DNA methylation and histone modification; 93 
through methylation and acetylation of histones) resulting in changes to chromatin 3D 94 
structure, and the translational level  (ncRNAs; microRNAs (miRs), long non-coding RNAs 95 
(lncs), small nucleolar RNAs (snoRNAs); mRNA editing and mRNA stability) affecting 96 
protein expression (reviewed [10]).  97 
 98 
DNA Methylation 99 
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The  methylation of base cytosines (5-methyl cytosine) within CpG containing nucleotides is 100 
a stable epigenetic marks that results in gene silencing [11] and is known as DNA 101 
methylations. In previous years genome-wide DNA methylation studies have concentrated 102 
principally upon cartilage tissue. This is because it is composed of a single cell type; the 103 
chondrocyte, making it less problematic to study. Hence genuine alterations in DNA 104 
methylation can be assessed as these are not affected by disease-related changes in cell 105 
proportions [12].   Table 2 summarises the genome-wide DNA methylation studies published 106 
in the last year. OA-related studies prior to this have already been discussed [13]. The 107 
methodology of choice published continues to be the Human IlluminaMethylationBead-Chip 108 
450K array. Studies published in the last year are distinct from those previously reported as  109 
currently experiments involving other tissues such as subchondral bone [14] and fibroblast-110 
synoviocytes [15] are being undertaken. Additionally a number of studies have investigated 111 
OA progression [14, 16]. These investigated different regions within the tibial plateau as 112 
indicators of OA development. Methylation changes appeared to occur at a later stage of 113 
disease indicating that these are a consequence rather than a cause of OA. Similar to other 114 
studies [17] it was found that joint specific methylation patterns are  independent of disease, 115 
indicating location specific epigenetic marks [15]. However Ai et al. [15] also identified  OA 116 
or rheumatoid arthritis (RA) specific  methylation patterns. 117 
 118 
Three studies undertook RNA sequencing in parallel with DNA methylation analysis [15, 18, 119 
19]. This is becoming an increasingly used methodology enabling methylation variation, and 120 
the functional consequences at the transcriptional level to be assessed together. Each of these 121 
studies found different correlations between the  DNA methylated genes within contrasts and 122 
level of gene expression, both identified and their direction. It appears that in these studies 123 
most CpG sites with variable methylation are unconnected to gene expression variation. The 124 
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properties of these associations seem complex, with the location of CpG probes with respect 125 
to the corresponding gene offering little information with regards to the type of correlation. 126 
All studies in Table 2 contain limited sample sizes which reduces the ability to detect weak 127 
associations that may be pertinent to our understanding of this epigenetic mark in OA.  128 
The role of the epigenetic clock was investigated in OA for the first time (including work by 129 
Jefferies et al [20]). DNA methylation age-measures (DmAM), which combine methylation 130 
levels at CpG sites that experience methylation changes with ageing are potential biomarkers 131 
of epigenetic ageing [21]. The potential role of DNA methylation in cartilage ageing in OA 132 
was investigated. Studying methylation changes at both the local and systemic level Vidal-133 
Bralo et al. identified premature epigenetic ageing due to DNA methylation changes specific 134 
to OA cartilage [22]. Interestingly similar findings were not extended to blood cells and bone.  135 
Other joint tissues and larger sample sizes are required for clarification of these interesting 136 
findings. 137 
 Table 2. Genome-wide methylation studies in OA 138 
Study; joint 
and disease 
Number of 
donors 
Tissue/cell 
type 
Contrasts Technique Results 
(DE 
DMS) 
Refere
nce 
Knee; OA 
progression 
12 donors; 
early, inter, 
late OA from 
each 
Subchondral 
bone 
Early vs 
inter, 
Early vs 
severe, inter 
vs severe 
450K array 72, 
397, 
257  
Zhang 
et al., 
2016 
[14] 
Knee; OA 
progression 
12 donors; 
early, inter, 
late OA from 
each 
Chondrocytes Early vs 
inter, 
Early vs 
severe 
450K array 0, 
519 
Zhang 
et al., 
2016 
[16] 
Hip; fracture 
and OA 
22 fracture, 18 
OA 
MSCs Fracture vs 
OA 
450K 
array* 
parallel 
RNASeq 
9038 Del 
Real et 
al., 
2017 
[19] 
Hip and 
knee; RA, 
OA 
30 RA; 12 
knee, 10 hip 
16 OA;10 
knee, 5 hip 
Fibroblast-
like 
synoviocytes 
RA vs OA 
RA hip vs 
RA knee 
RA vs OA 
450K 
array* 
parallel 
RNASeq 
1714 
3739 
9589 
2172 
Ai et 
al., 
2016 
[15]  
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knee 
RA vs OA 
hip 
Knee; 
normal and 
OA 
11 normal, 12 
OA 
Cartilage Normal vs 
OA 
450K 
array* 
parallel 
RNASeq 
929 Alvarez
-Garcia 
et al., 
2016 
[18] 
Knee and 
hip;  
cartilage 
neocartilage 
derived 
from knee 
chondrocyte
s or hip 
MSCs 
6 knee, 6 hip 
cartilage; 4 
neocartilage 
from MSCs, 4 
neocartilage 
from 
chondrocytes 
Chondrocytes 
and MSCs 
Neocartilage 
MSC vs 
chondrocytes 
450K array 5884 Bomer 
et al., 
2016 
[23] 
OA; osteoarthritis, RA; rheumatoid arthritis, MSC; mesenchymal stem cells, DE DMS; 139 
differentially expressed DNA methylation sites. 140 
Histone modifications 141 
DNA is wrapped around an octamer of histone proteins forming the complex structure of 142 
chromatin. Posttranscriptional modifications of the histone tails can alter the accessibility of 143 
chromatin, and change gene transcription by allowing promoter site transcription factor 144 
binding and initiating transcription [24]. These modifications are dynamic meaning that these 145 
changes can be altered in response to stimuli. Posttranslational modifications occur through 146 
sets of enzymes such as histone deacetylases (HDACs). Two studies in the last year have 147 
investigated the effects of pharmacological intervention points through targeting these 148 
enzymes in order to provide insights into the role of epigenetics in OA and identify 149 
exploitable targets for treatments. In one study Vorinostat, a HDACI and II inhibitor was 150 
demonstrated as  a suppressor of catabolic marker expression in OA through inhibition of IL-151 
6 signaling [25]. Further work by the group showed that it functioned through increased 152 
recruitment of CEBPalpha to the MCPIP1 promoter, relieving the miR-9-mediated inhibition 153 
of MCPIP1 expression in OA chondrocytes [26]. A further study found that H3K27me3 154 
demethylases regulated in vitro chondrocyte activity in OA through the inhibition of TGFβ 155 
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induced gene expression. Targeting the inhibition  of H3K27me3 demethylases could provide  156 
potential OA therapeutics [27]. 157 
 158 
NON-CODING RNAs 159 
MicroRNAs 160 
MiRs are small (19-25 nucleotides (nt)) ncRNAs that function at the post-transcriptional level 161 
by binding and supressing the expression of specific mRNA targets [28]. MiRs are involved 162 
in different cellular pathways, highlighting the role of these molecules in maintaining tissue 163 
homeostasis as well as being implicated in disease [29]. Over the last few years the roles of 164 
miRs in OA has been reviewed extensively with studies identifying numerous miR candidates 165 
involved in cartilage homeostasis and/or OA pathogenesis [30-34]. Most of the studies 166 
published during the last year focused on miRs which have been previously reported to play a 167 
role in chondrocyte function and OA, such as miR-140 [35] miR-29 [32], miR-34a [34, 36], 168 
miR-9 [37, 38] and miR-98 [33, 39]. Identification of miR-181a-5p and miR-4454 as 169 
mediators of facet cartilage degeneration was presented at OARSI 2017 [40]. However, some 170 
studies reported for the first time the implication of specific miRs in OA, such as miR-15-5p 171 
[41] and miR-410 [42]. The methodologies remain similar, with human primary OA 172 
chondrocytes treated with miR mimics and/or inhibitors and qRT-PCR being commonly 173 
utilized in order to measure the expression of both specific miRs and cartilage-associated 174 
genes (Table 3, a full summary table of MiR studies reviewed is in Supplementary File 1). 175 
Additionally many of these studies identified and validated using luciferase reporter assays  176 
putative target genes of the miRs in question, and these findings were usually integrated into, 177 
or associated with important signalling pathways, such as the NF-kB and AP1 (c-fos/c-jun) 178 
[43, 44].  179 
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Regarding genome-wide approaches undertaken in the last year, four studies used microarray 180 
analysis to test for differentially expressed (DE) miRs in OA chondrocytes treated with 181 
various stimulating factors or whole mouse joints from a destabilization of the medial 182 
meniscus (DMM) model. Each study identified several DE miRs [31, 32, 45, 46]. One study 183 
undertook a next generation sequencing approach using human cartilage from different OA 184 
stages [47]. Finally, Kung et al. (2017) measured DE circulating miRs in the serum of DMM 185 
mice with the results suggesting that two miRs, miR-3102-5p and miR-3081-5p, 186 
demonstrated higher expression in late stage OA compared to controls, although findings 187 
were not validated [48]. A role of circulating miRs in OA was presented by Rousseau et al at 188 
OARSI 2017 [49]. 189 
Although the number of research publications and miRs involved in OA pathogenesis is 190 
rising constantly, no miR biomarkers have been validated that could be utilised in early 191 
diagnosis of the disease. This is due partially to the fact that OA is a multifactorial 192 
heterogeneous disease. As a result, the miR signature responds differently to the type of 193 
stimuli involved in OA initiation and progression. Similarly, therapeutic options based on 194 
miRs are also hindered by the heterogeneity of the disease, the need for targeted delivery 195 
approaches and the lack of evidence on the molecular and cellular processes that orchestrate 196 
OA. This clearly highlights the importance of an in-depth understanding of the signalling 197 
pathways behind OA but at the same time steps should be taken to integrate the multiple miR 198 
findings into the clinical setting, especially for some of the well-studied miRs which provide 199 
promising therapeutic targets.  200 
Table 3. Selected miRs studies focusing on cartilage associated genes  201 
MicroRNA Target genes Cellular/Biological process Tissue Reference 
mir-9 SIRT1 Oxidative stress-induced 
chondrocyte death 
 
Cartilage D'Adamo et al. (2017) 
[37] 
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miR-15a VEGFA 
 
Matrix degradation 
 
Cartilage Chen et al. (2017) [41] 
miR-23a SMAD3 OA development Cartilage Kang et al. (2016) [50] 
miR-26a/b KPNA3 NF‑κB signaling pathway Cartilage Yin et al. (2017) [44] 
miR-29 
family 
FZD3, FZD5, 
DVL3, FRAT2, 
CK2A2 
OA development and 
progression 
Cartilage Le et al. (2016) [32] 
miR-34a SIRT11 Chondrocyte apoptosis Cartilage Yan et al. (2016) [34] 
miR-98 BCL-2 Chondrocyte apoptosis Cartilage Wang et al. (2016) [39] 
miR-221 SDF1 ECM degradation Cartilage Zheng et al. (2017) [47] 
miR-381 HDAC4 Chondrocyte Hypertrophy Mouse forelimbs Chen et al. (2016) [51] 
mir-410 WNT3A Chondrogenic differentiation Bone marrow 
MSCs 
Zhang et al. (2017) [42] 
 202 
Other non-coding RNAs  203 
The relevance of ncRNAs to OA has mainly focussed on the widespread disruption of miR 204 
expression. However we are beginning to understand and study the nature and involvement of 205 
other ncRNAs in OA such as piwi-interacting RNAs (piRNAs), snoRNAs and large-206 
intergenic non-coding RNAs (lincRNAs). In the last year an insight into their potential roles 207 
in OA has emerged for the first time. 208 
SnoRNAs mediate enzymatic modifications of other RNA species, such as ribosomal RNAs, 209 
by forming ribonucleoprotein complexes with enzymes [52]. These modifications include 210 
ribose methylation and pseudouridylation. Little data exists on the role of these RNA species 211 
in OA. A pubmed search gave only one result regarding the implication of snoRNAs in OA 212 
during last year; Steinbusch et al. (2017) undertook snoRNAseq analysis in OA joints and 213 
serum from DMM mice [53]. Several DE snoRNAs, such as SNORA64, SNORD46 and 214 
SNORD116, were identified and validated and the authors concluded that snoRNAs could be 215 
used as potential biomarkers for joint degeneration.  216 
PiRNAs (24-32 nt) form RNA-protein complexes with piwi proteins and are linked to both 217 
epigenetic and post-transcriptional gene silencing of genetic elements, thus protecting cells 218 
from invasive transposable elements in the germline [54]. For the first time piRNAs and their 219 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
binding partners were identified in OA and RA synovial fibroblasts and synovial fluid. The 220 
study concluded that PIWI/piRNA pathways are involved in innate immunity and may have a 221 
role in the pathogenesis of RA [55]. 222 
 223 
Long non-coding RNAs 224 
There has been an increase in studies published on lncRNAs in OA (up from four in 2015-225 
2016 to 11 in the same period 2016-2017). LncRNAs are an RNA molecule greater than 200 226 
nt. Dysregulated expression of lncRNAs performs a significant role in inflammation-related 227 
diseases, and has been demonstrated as being associated with OA progression and cartilage 228 
degradation (reviewed [56]). Two discovery studies were undertaken (Table 4). In one study 229 
a role in mediating inflammation driven cartilage degeneration for the novel lncRNAs 230 
CILinc01 and CIinc02 was identified [57]. Additionally a number of targeted lncRNA studies 231 
on both novel [36, 58] and previously studied lncRNAs [59, 60] were undertaken (Figure 1).  232 
Table 4. Long non-coding RNA discovery studies in OA  233 
Study Species Technology Method and N Findings Reference 
Post-traumatic 
OA 
Mouse RNA 
sequencing 
Joints; 1 day 
(n=5), 1(n=5), 
6 (n=3), 12 
(n=3) week 
post injury 
18 DE 
lncRNAs (at 
least one time 
point) 
Chang et al., 
2016 [61] 
Normal versus 
OA cartilage 
Human RNA 
sequencing 
Chondrocytes;  
hip OA±IL-1β 
(n=3 each) 
983 lncRNAs 
identified, 125 
DE 
Pearson et al., 
2016 [57] 
N; number donors, OA; osteoarthritis, IL-1β; interleukin 1β, DE; differentially expressed 234 
Emerging areas for future study 235 
Understanding the biology of RNA modifications represents one of the next potential 236 
frontiers in arthritis research. [62].  We realise that the control of the transcriptome is 237 
pertinent to the diverse aspects of gene regulation, cellular functionality and development, 238 
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and that alterations can result in disease. There is an emerging field of research termed 239 
‘epitranscriptomics’; the identification and characterisation of changes in biochemical RNA 240 
modifications that do not comprise alterations to the RNA sequence. Epitranscriptomic 241 
analysis  was the Nature method of the year 2016 [63]. Epitranscriptomics includes 242 
modifications to rRNA, tRNA and mRNA. However the role and function of snoRNAs, 243 
lncRNAs, anti-sense, and small RNAs derived from tRNAs remains largely unrealized. 244 
A further layer of gene expression control is through alterations in genetic information by 245 
RNA editing (epitranscriptomics)or via the establishment of RNA covalent modifications. 246 
Interestingly disease-related exome sequencing has contributed to the pivotal attributions of 247 
mutations in RNA modifying enzymes to many human diseases [64].  In OA the risk gene fat 248 
mass and obesity associated protein (FTO) is an m6A mRNA eraser [65]. Improved 249 
technologies (reviewed [66]) will enable RNA modifications signatures and dynamics to be 250 
discovered. 251 
Within the context of this emerging discipline (as an additional molecular level on control in 252 
physiology and disease), and with expanding omics technological advances the discipline of 253 
‘systems biology’ is becoming increasingly influential in our understanding of OA [67] 254 
(Figure 2).  Its aim is to systematically and comprehensively obtain quality data from all 255 
biological hierarchies’ whist assimilating the data to develop predictive models of the system. 256 
Some of the challenges of systems biology in OA research include that not all tissues are 257 
evenly represented in systems studies, not all levels are explored systematically (for instance 258 
there are limited studies on histone modifications) and there is difficulty in integrating and 259 
correlating the different levels of the system. These challenges thus represent further 260 
opportunities to address.  261 
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Figure Legend 459 
Figure 1.  LncRNA studies in OA targeting different mechanisms of action of lncRNAs . 460 
Three functions of lncRNAs have been investigated; through acting as sponges for miRs, 461 
transcriptional activation and repression and the regulation of the chromatin state (miR; 462 
microRNA, TMSB4; thymosin-β4, SMSCs; synovium-derived mesenchymal stem cells, IL-463 
1β; interleukin 1β, MMP; metalloproteinase). References; 1. Zhang et al., 2016 [36], 2. Liu et 464 
al., 2016 [58], 3. Zhang et al., 2017 [60], 4. Zhang et al., 2016 [59]. 465 
Figure 2. Schematic diagram of a systems orientated approach to develop novel diagnostic 466 
and treatment solutions to OA. Omics studies enable pictures of the biological hierarchy. Red 467 
boxes highlight the areas covered in this review [67]. 468 
Supplementary Files 469 
Supplementary File 1 Summary table of miR studies reviewed. 470 
 471 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Figure Legend 1 
Figure 1.  LncRNA studies in OA targeting different mechanisms of action of lncRNAs . 2 
Three functions of lncRNAs have been investigated; through acting as sponges for miRs, 3 
transcriptional activation and repression and the regulation of the chromatin state (miR; 4 
microRNA, TMSB4; thymosin-β4, SMSCs; synovium-derived mesenchymal stem cells, IL-5 
1β; interleukin 1β, MMP; metalloproteinase). References; 1. Zhang et al., 2016 [34], 2. Liu et 6 
al., 2016 [53], 3. Zhang et al., 2017 [55], 4. Zhang et al., 2016 [54]. 7 
Figure 2. Schematic diagram of a systems orientated approach to develop novel diagnostic 8 
and treatment solutions to OA. Omics studies enable pictures of the biological hierarchy. Red 9 
boxes highlight the areas covered in this review [62]. 10 
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